1. 23andMe and GSK in joint effort to mine customer DNA data with an eye to drug development — Biogen earnings — Speculation on JNJ opioid settlement total — See more on our front page news

    TRY TWO WEEKS OF OUR EMAIL NEWS HEADLINES FOR FREE
    Dismiss Notice
  2. Dealing with a potential legal issue at work?Ask an Employment Attorney -- a chance to discuss employment-related legal issues with a practicing attorney with over 20 years in employment law experience.
    Dismiss Notice

The infusion model is about to die

Discussion in 'Janssen' started by anonymous, Oct 25, 2018 at 9:45 PM.

Tags: Add Tags
  1. anonymous

    anonymous Guest

    Look up in today’s news “
    Trump outlines new plan to lower Medicare drug prices, end 'rigged' system

    Goodbye over priced infusion drugs from JNJ. That should pretty much kill what’s left of Rheum and GI.
     

  2. anonymous

    anonymous Guest

    This is the best news our new NSD could get. She doesn't have to learn it now and can talk about reach and frequency and call average and callsper day. This is gonna suck.
     
  3. anonymous

    anonymous Guest

    Since she is from over the counter sales, she will recycle the old 1999 playbook from primary care. More reach + more frequency = more sales. She will be regarded as a genius with this novel approach!
     
  4. anonymous

    anonymous Guest

    The new NSD is here to organize the final performance of “The shit show on ice”.
     
  5. anonymous

    anonymous Guest

    That means an automatic cost saving mandatory switch to cheapest in the class. The layoffs are going to be deep and wide on this one. So long high priced biologics, hello low cost providers.
     
  6. anonymous

    anonymous Guest

    HR insider here...layoffs are confirmed by end of Q1 2019.
     
  7. anonymous

    anonymous Guest

    We need to be honest here. Reps don’t work a full week and never did. The work load, thanks to partnering, is rediculous and most reps struggle to keep their manager busy on ride alongs. Sales reps could be reduced by 75% and have zero impact on sales. That goes for sales managers as well. Most of us have really forgotten how to really work. SMDs and NADs are on permanent vacation. HPADs are a joke. The facts speak loudly. Slash away without any repercussions.
     
  8. anonymous

    anonymous Guest

    Absolutely. But this has been fact for years and nobody wants to speak the truth or acknowledge it. Too much risk in JNJ being an outlier. Keep your head down and mouth shut and try to get to 55 and 10.
     
  9. anonymous

    anonymous Guest

    There goes the $ switch of Remicade patients over to Aria. What a plan that was given Aria doesn’t hold clinically and is 2x the price. Ever read the Aria trial “Go Save”. Leadership MIA in the building for the last 10 years ?
     
  10. anonymous

    anonymous Guest

    doubtful for Q1. 100% of the time when a realignment has occurred at COBI/JBI it was at the end of Q2. This also makes since because we are on a 6 month comp plan... We have a bunch of contract reps as a buffer as well.. Once the contract reps are cleared out then we are next on the list...
     
  11. anonymous

    anonymous Guest

    What's up with the DOME re-org?
     
  12. anonymous

    anonymous Guest

    Slash it, slash it, slash it. I will enjoy watching the carnage while eating pork cracklins...
     
  13. anonymous

    anonymous Guest

    IOI model won’t ever die now that we can sell on the spread. Clearly Docs make more cheese with us.
     
  14. anonymous

    anonymous Guest

    GIs aren’t liking the model with Stelara. We need to get more Doc administered drugs to sell. It’s that simple.
     
  15. anonymous

    anonymous Guest

    Smart docs have known for several years the infusion model is dead and have been planning accordingly....


    .
     
  16. anonymous

    anonymous Guest

    In the West Rheumatology we are directed to use the “White Board” to show how much they can make on contract rebates ie ... CPP. Then just erase white board. No leave behind- never happened- Medicare - What ?
     
  17. anonymous

    anonymous Guest

    It’s perfectly legal so stop trying to turf stuff up. We are doing nothing more than writing down what the customer says and showing it to them to see if what they said makes sense to them. I’m sure other Districts are doing the same in the West. So stop! Or else!,
     
  18. anonymous

    anonymous Guest

    It's over


    .
     
  19. anonymous

    anonymous Guest

    Good bye Rhuematology. It has been a fun ride. Abbvie here I come.